British Patient Capital operates a £375m programme called Future Fund: Breakthrough, co-investing with private sector investors in R&D-intensive UK companies.
The Series A round included backing from British Patient Capital, F-Prime Capital, and Sofinnova Partners.
"Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide. Through Future Fund: Breakthrough, we are delighted to support this truly innovative British business with the funding to take the business to the next level."
GIC led the Series E round, which values the decision intelligence provider at $1.8bn.
"After closing our Series D investment round, Quantexa has been on a transformational journey, accelerating the growth of our global software business and firmly establishing our leadership position in the emerging Decision Intelligence category. In a challenging market we have doubled our ARR, our user base, and continue to penetrate new markets and industries. This infusion of capital will fuel further innovation, diversification, and expansion, and opens exciting options for our future."
Oxx led the Series B round with participation from institutional and returning investors to fund product development and global expansion.
"Once again, we were blown away by the interest we received from investors, but as we carve our niche in the market, we remain steadfast in being selective of shareholders whose values and ambition align closely with our own. In spite of the economic downturn, we are encouraged that some of Europe’s most reputable investors believe in, and are keen to financially support, CyberSmart’s mission to protect and empower the underserved SME market against cybercrime. More importantly, we are delighted that they trust us to deliver on that vision, and I look forward to seeing how much we can accomplish in the year ahead."
The oversubscribed round was led by Bosch Ventures with backing from Porsche SE and British Patient Capital.
"The support of leading technology investors enables us to realise our vision of a quantum computer built using standard foundry processes. This support, along with the continuing UK national quantum programme and European initiatives, provides a step-change in our capabilities. We have assembled a world leading team and with the funding and support in place, we are ready to scale and deliver on our vision."
The medtech firm has raised $36m in a round led by Oppenheimer Holdings to accelerate its product pipeline and scale American operations.
"We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies that will help clinicians shorten patients' diagnostic and treatment journeys,"
